Pegaptanib

Drug Profile

Pegaptanib

Alternative Names: anti-VEGF aptamer; BLO 021; EYE-001; Macugen; NX-1838; Pegaptanib octasodium; Pegaptanib sodium

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Bausch Health Companies; Eyetech Inc.; Gilead Sciences; Pfizer
  • Class Eye disorder therapies; Nucleotide aptamers
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration
  • No development reported Diabetic macular oedema; Diabetic retinopathy
  • Discontinued Choroidal neovascularisation; Retinal vascular occlusion

Most Recent Events

  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
  • 24 Jun 2018 Biomarkers information updated
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top